Gelteq shares surge 28.31% premarket after positive preclinical results show 38–45% bioavailability boost.

Gelteq surged 28.31% in premarket trading following the announcement of positive preclinical results demonstrating its gel-based delivery technology enhanced the bioavailability of a reference antihistamine by 38–45%. The study highlighted a significant increase in systemic exposure (AUC) and peak concentration (Cmax) while maintaining comparable time-to-peak (Tmax), validating the platform’s potential to improve drug absorption and patient compliance. CEO Nathan Givoni emphasized the results as a transformative milestone, positioning the company to pursue FDA approval for an antihistamine product and expand into broader water-soluble drug classes. The findings, applicable to a wide range of pharmaceutical applications, underscored Gelteq’s commercial potential and reinforced investor confidence in its proprietary technology. The preclinical data, released on November 24, 2025, directly aligned with the stock’s sharp premarket rise, driven by optimism over regulatory pathways and partnership opportunities.